BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $92.76 million versus the consensus estimate of $85.82 million.

GUIDANCE:

BioCryst Pharma sees FY2024 revenue of $390-400 million, versus the consensus of $395.1 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.